Eli Lilly & Co., a leading developer of pharmaceutical products that help people live longer, healthier and more active lives, took top honors for its support of clinical research education at the 2008 Annual Meeting of the Center for Information and Study on Clinical Research Participation (CISCRP) in June.
(DEDHAM, MA)- Eli Lilly & Co., a leading developer of pharmaceutical products that help people live longer, healthier and more active lives, took top honors for its support of clinical research education at the 2008 Annual Meeting of the Center for Information and Study on Clinical Research Participation (CISCRP) in June.
Lilly was awarded CISCRP’s Medical Heroes Awardfor its investment of people and funding in a wide span of critical initiatives including the AWARE for All Clinical Research Education program; new educational materials; and the development and testing of CISCRP’s new Medical Heroes public service campaign. The aptly named Medical Heroes Award links Lilly’s support with CISCRP’s groundbreaking efforts to transform the image of the clinical research volunteer from “guinea pig” to “medical hero.” In addition, Lilly has aided the development of CISCRP’s disease-specific DVD’s for African American and Hispanic audiences about the role of clinical research participation in improving minority health.
AstraZeneca, the Lupus Foundation, Ogilvy HealthWorld, and PharmaNet also were honored for their contributions to the development of new CISCRP Educational Materials, including: two specialized brochures for African-American and Hispanic audiences; 10 foreign language brochures for people in 12 different countries; and the creation of disease-specific DVDs about the risks and benefits of volunteering for clinical research studies.
Six Philadelphia academic medical centers and hospitals received CISCRP’s award for Outstanding Support of Public Outreach and Community Building for their work on behalf of the organization’s mission of educating and empowering people to make informed decisions about clinical research participation.
Children’s Hospital of Philadelphia, Drexel University School of Medicine, Fox Chase Cancer Center, Temple University, Thomas Jefferson University, and the University of Pennsylvania School of Medicine were recognized for their collaborative support and co-sponsorship of the highly successful AWARE for All-Philadelphia Clinical Research Education Day in April.
The highly successful program was attended by some 400 guests and provided free public workshops about health and the role of the clinical research volunteer. Many of the speakers and presenters were researchers and healthcare professionals from the co-sponsoring organizations.
The independent, non-profit organization, CISCRP, is a national leader in promoting public trust of the clinical research enterprise and raising public awareness of clinical research’s role in improving public health. To find out more, please visit www.CISCRP.org, email info@ciscrp.org, or phone 1-781-326-3400 or Toll Free: 1-888-CISCRP3 (247-2773).
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.